Gemcitabine (Gemox) + Oxaliplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unknown Primary Neoplasms
Conditions
Unknown Primary Neoplasms
Trial Timeline
Feb 1, 2004 → Jan 1, 2010
NCT ID
NCT00353145About Gemcitabine (Gemox) + Oxaliplatin
Gemcitabine (Gemox) + Oxaliplatin is a phase 2 stage product being developed by Sanofi for Unknown Primary Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00353145. Target conditions include Unknown Primary Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00353145 | Phase 2 | Completed |
Competing Products
9 competing products in Unknown Primary Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carboplatin + Gemcitabine + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Etoposide + Gemcitabine + Irinotecan + Paclitaxel + Carboplatin | Eli Lilly | Phase 3 | 77 |
| paclitaxel/carboplatin + cetuximab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| 177Lu-FAP-2286 | Novartis | Phase 2 | 52 |
| Oxaliplatin + Capecitabine | Roche | Phase 2 | 52 |
| Alectinib + Vismodegib + Ipatasertib + Olaparib + Erlotinib + Bevacizumab + Vemurafenib + Cobimetinib + Trastuzumab Subcutaneous (SC) + Pertuzumab + Atezolizumab + Carboplatin + Paclitaxel + Cisplatin + Gemcitabine + Entrectinib + Ivosidenib + Pemigatinib | Roche | Phase 2 | 52 |
| Sintilimab | Innovent Biologics | Phase 2 | 51 |
| Diosmectite (Smecta®) | Ipsen | Phase 1 | 30 |